Praziquantel: a unique pharmaceutical challenge

吡喹酮：独特的制药挑战

• 批准号: LP0883419
• 负责人: A/Prof Matthew Todd
• 金额: $ 22.07万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-02-18 至 2012-12-07
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP0883419
• 关键词: Praziquantel; unique; pharmaceutical; challenge

Generating effective and affordable drugs for the treatment of tropical diseases is a huge public health challenge. We will pioneer an open source approach to collaborative research in drug discovery. We aim to discover an inexpensive route to an important pharmaceutical so that it can be greatly improved and distributed to the affected populations for a realistic price. Success in this project will improve the lives of millions of sufferers of this disease, and demonstrate a new way of doing research on drugs for related diseases such as malaria.

为治疗热带疾病提供有效和负担得起的药物是一项巨大的公共卫生挑战。我们将开创一种开源的方法来进行药物发现的合作研究。我们的目标是发现一种廉价的重要药物，以便它可以大大改善，并以现实的价格分发给受影响的人群。该项目的成功将改善数百万这种疾病患者的生活，并展示一种研究疟疾等相关疾病药物的新方法。